TYRA
Tyra Biosciences Inc
NASDAQ: TYRA · HEALTHCARE · BIOTECHNOLOGY
$33.79
-3.64% today
Updated 2026-04-29
Market cap
$2.01B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.01
Dividend yield
—
52W range
$9 – $41
Volume
1.2M
Tyra Biosciences Inc (TYRA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | $8000.00 | $47000.00 | $140000.00 | $296000.00 | $353000.00 | $519000.00 | $546000.00 |
| Gross profit | $-8000.00 | $-47000.00 | $-140000.00 | $-296000.00 | $-353000.00 | $-519000.00 | $-546000.00 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $1.79M | $7.20M | $20.64M | $43.01M | $62.52M | $80.08M | $102.93M |
| SG&A | $1.33M | $2.09M | $5.65M | $15.92M | $17.43M | $24.10M | $29.83M |
| Operating income | $-3.12M | $-9.30M | $-26.29M | $-58.93M | $-79.94M | $-104.18M | $-132.76M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-3.11M | $-9.25M | $-26.15M | $-58.63M | $-79.59M | $-103.66M | $-119.40M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-3.12M | $-9.30M | $-26.29M | $-58.93M | $-79.94M | $-104.18M | $-119.95M |
| Interest expense | $1000.00 | $1000.00 | $140000.00 | $296000.00 | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-4.06M | $-9.31M | $-26.14M | $-51.72M | $-69.13M | $-86.48M | $-119.95M |
| Net income growth (YoY) | — | -129.5% | -180.7% | -97.9% | -33.7% | -25.1% | -38.7% |
| Profit margin | — | — | — | — | — | — | — |